Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

ABSTRACT: Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

PROVIDER: PRJNA597784 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10769271_1.fastq.gz	Fastqsanger.gz
	SRR10769271_2.fastq.gz	Fastqsanger.gz
	SRR10769272_1.fastq.gz	Fastqsanger.gz
	SRR10769272_2.fastq.gz	Fastqsanger.gz
	SRR10769273_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 58

Similar Datasets

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

Project description:Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, an extracellular inhibitor of the canonical Wnt signaling pathway, expressed in osteocytes. Romosozumab results in increased bone formation and decreased bone resorption and has been approved in several countries for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Sclerostin is also expressed in aortic vascular smooth muscle cells, the function of which is unclear but has been proposed to be an inhibitor of vascular calcification, atheroprogression, and associated inflammation. A slight increase in serious cardiovascular adverse events (CV AEs) was observed in romosozumab-treated subjects in a clinical trial comparing alendronate with romosozumab (ARCH; NCT01631214) but was not observed in a placebo-controlled trial (FRAME; NCT01575834). To investigate biological plausibility of the role of romosozumab in cardiovascular disease, a comprehensive nonclinical package with additional cardiovascular studies was conducted including studies in two murine models of atherosclerosis. Results of these studies demonstrated that the effects of romosozumab or a surrogate sclerostin antibody were either a direct or indirect consequence of its pharmacodynamic effects on bone. There were with no functional or morphologic effects on the cardiovascular system in animal models in the presence or absence of atherosclerosis. The totality of these nonclinical data has not identified a biologically plausible mechanism to explain the increase in serious CV AEs in the ARCH trial.

2020-12-31 | GSE142634 | GEO

Detection of potential microRNA biomarker for postmenopausal osteoporosis

Project description:Recent studies have shown that microRNAs (miRNAs) are implicated in the development of postmenopausal osteoporosis, implying potential biomarkers. We performed a microarray-based expression scanning to search for potential circulating miRNA biomarkers for postmenopausal osteoporosis as whole blood obtianed from patients was used. MiRNA expression in the whole blood of 23 Chinese postmenopausal women with osteopenia and that of 25 Chinese postmenopausal women with osteoporosis. After total RNA was extracted, all of the RNA extraction samples were seperately pooled into six subgroups according to the T-score measurement.

2014-12-23 | E-GEOD-64433 | biostudies-arrayexpress

Genes expression profiles of postmenopausal osteoporosis

Project description:Investigate genes expression profiles of postmenopausal osteoporosis in bone(femur)

2023-04-29 | GSE230665 | GEO

Detection of potential microRNA biomarker for postmenopausal osteoporosis

2014-12-23 | GSE64433 | GEO

Genes expression profiles of postmenopausal osteoporosis with kidney Yin deficiency

Project description:Investigate genes expression profiles of postmenopausal osteoporosis with kidney Yin deficiency in peripheral blood By TCM syndrome, 10 patients with postmenopausal osteoporosis were divided into three groups: kidney Yin deficiency (n=4), kidney Yang deficiency (n=3), non-kidney deficiency (n=3), another 3 healthy postmenopausal women also were selected as control group. Whole human genome oligo microarray were applied to explore gene expression difference of the groups. Kidney Yin deficiency group was compared with other three groups respectively.

2014-03-23 | E-GEOD-56116 | biostudies-arrayexpress

Genes expression profiles of postmenopausal osteoporosis with kidney Yin deficiency

Project description:Investigate genes expression profiles of postmenopausal osteoporosis with kidney Yin deficiency in peripheral blood

2014-03-23 | GSE56116 | GEO

Identification of exosomal circRNAs as potential biomarkers for postmenopausal osteoporosis

Project description:Background: Osteoporosis is one of the most common chronic diseases around the world, especially in postmenopausal women. Circular RNAs (circRNAs) are emerging as important regulators in human disease. The aim of the present study was to analyze circRNA expression profiles in osteoporosis and to explore the clinical significance. Methods: The serum samples were collected from osteoporosis patients and healthy people. The circRNA array was performed to screen for differentially expressed circRNAs. The mRNA expression levels of target genes were analyzed by quantitative real-time PCR (qRT-PCR). Results: Hsa_circ_0006859 was identified as one of the most upregulated circRNAs in the microarray analysis. Hsa_circ_0006859 in exosome was upregulated in osteoporosis patients compared with healthy controls. Hsa_circ_0006859 could differentiate osteopenia or osteoporosis patients from healthy controls with high sensitivity and specificity. Conclusion: Exosomal hsa_circ_0006859 is a potential biomarker for postmenopausal osteoporosis.

2020-11-13 | GSE161361 | GEO

Genes expression profiles of postmenopausal osteoporosis

Project description:Genes expression profiles of postmenopausal osteoporosis

| PRJNA962097 | ENA

Transcriptomic analysis of the bone reveals the mechanism of Desertliving Cistanche herb in ovariectomized rats of postmenopausal osteoporosis

Project description:To investigate the function of Desertliving Cistanche herb in the postmenopausal osteoporosis, we established ovariectomized rats in which both ovaried were removed.We performed gene expression profiling alalysisi using date obtained from RNA-seq of ovariectomized rats of postmenopausal osteoporosis.

2023-12-31 | GSE208290 | GEO

Bone metabolism-related serum miRNAs to diagnose postmenopausal osteoporosis in middle-aged and elderly women

Project description:Serum miRNAs could be powerful classifiers for the detection of patients with postmenopausal osteoporosis.

2022-05-01 | GSE201543 | GEO